MedPath

Cilostazol

Generic Name
Cilostazol
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C20H27N5O2
CAS Number
73963-72-1
Unique Ingredient Identifier
N7Z035406B
Background

Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.

Indication

Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).

Associated Conditions
Intermittent Claudication
Associated Therapies
-

Pharmacodynamic Study of Cilostazol in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2015-09-18
Last Posted Date
2021-10-13
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
77
Registration Number
NCT02554721

Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI

Not Applicable
Completed
Conditions
Migraine Without Aura
Migraine Headache
Interventions
Drug: Feraheme
Drug: Cilostazol
Other: USPIO-MRI
Other: BBI-MRI
First Posted Date
2015-09-15
Last Posted Date
2022-07-27
Lead Sponsor
Danish Headache Center
Target Recruit Count
34
Registration Number
NCT02549898
Locations
🇩🇰

Rigshospitalet Glostrup, Glostrup, Denmark

A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)

Phase 2
Completed
Conditions
Mild Cognitive Impairment
Interventions
Drug: Placebo
Drug: Cilostazol
First Posted Date
2015-07-08
Last Posted Date
2020-12-04
Lead Sponsor
National Cerebral and Cardiovascular Center, Japan
Target Recruit Count
166
Registration Number
NCT02491268
Locations
🇯🇵

National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache

Not Applicable
Completed
Conditions
Migraine
Interventions
First Posted Date
2015-07-01
Last Posted Date
2017-05-09
Lead Sponsor
Danish Headache Center
Target Recruit Count
30
Registration Number
NCT02486276
Locations
🇩🇰

Emma Katrine Hansen, Copenhagen, Glostrup, Denmark

PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study

Phase 4
Conditions
Brain Ischemia
Intracranial Hemorrhages
Interventions
First Posted Date
2015-06-26
Last Posted Date
2015-12-24
Lead Sponsor
Asan Medical Center
Target Recruit Count
800
Registration Number
NCT02483169

Lacunar Intervention Trial 1 (LACI-1)

Phase 2
Completed
Conditions
Cerebral Small Vessel Diseases
Cognitive Impairment
Stroke
Interventions
First Posted Date
2015-06-25
Last Posted Date
2018-01-19
Lead Sponsor
University of Edinburgh
Target Recruit Count
57
Registration Number
NCT02481323
Locations
🇬🇧

University of Edinburgh, Edinburgh, United Kingdom

🇬🇧

University of Nottingham, Nottingham, United Kingdom

Cilostazol-Simvastatin Drug Interaction Study

Phase 1
Conditions
Dyslipidemias
Peripheral Artery Disease
Interventions
First Posted Date
2015-04-30
Last Posted Date
2015-05-01
Lead Sponsor
Ajou University School of Medicine
Target Recruit Count
20
Registration Number
NCT02431013
Locations
🇰🇷

Ajou University Medical Center, Suwon, Gyeonggi, Korea, Republic of

Cilostazol After Lower Extremity Arterial Revascularization Trial

Phase 4
Terminated
Conditions
Peripheral Arterial Disease
Claudication (Finding)
Interventions
First Posted Date
2015-03-02
Last Posted Date
2018-11-23
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
20
Registration Number
NCT02374957
Locations
🇺🇸

Wake Forest Baptist Health, Winston-Salem, North Carolina, United States

Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM

Phase 3
Completed
Conditions
Coronary Artery Disease
Interventions
First Posted Date
2014-10-16
Last Posted Date
2017-10-09
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
100
Registration Number
NCT02266030
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Bundang-gu, Korea, Republic of

Induction of Migraine Aura With Cilostazol

Early Phase 1
Completed
Conditions
Migraine With Aura
Stroke
Interventions
Drug: Placebo
Drug: Cilostazol
First Posted Date
2014-10-01
Last Posted Date
2015-08-21
Lead Sponsor
Herlev Hospital
Target Recruit Count
16
Registration Number
NCT02253004
Locations
🇩🇰

Herlev Hospital, Dept Neurology, Herlev, Denmark

© Copyright 2025. All Rights Reserved by MedPath